GR3029831T3 - Use of dimethylbenzofurans and dimethylbenzopyrans as 5-ht 3? antagonists. - Google Patents

Use of dimethylbenzofurans and dimethylbenzopyrans as 5-ht 3? antagonists.

Info

Publication number
GR3029831T3
GR3029831T3 GR990400922T GR990400922T GR3029831T3 GR 3029831 T3 GR3029831 T3 GR 3029831T3 GR 990400922 T GR990400922 T GR 990400922T GR 990400922 T GR990400922 T GR 990400922T GR 3029831 T3 GR3029831 T3 GR 3029831T3
Authority
GR
Greece
Prior art keywords
pct
date jun
represents hydrogen
sec
formula
Prior art date
Application number
GR990400922T
Other languages
English (en)
Inventor
Daele Georges Henri Paul Van
Jean-Paul Rene Marie A Bosmans
Laerhoven Willy Joannes Ca Van
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of GR3029831T3 publication Critical patent/GR3029831T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Dental Preparations (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
GR990400922T 1992-11-20 1999-03-31 Use of dimethylbenzofurans and dimethylbenzopyrans as 5-ht 3? antagonists. GR3029831T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97901392A 1992-11-20 1992-11-20
PCT/EP1993/003206 WO1994012494A1 (en) 1992-11-20 1993-11-15 Use of dimethylbenzofurans and dimethylbenzopyrans as 5-ht3 antagonists

Publications (1)

Publication Number Publication Date
GR3029831T3 true GR3029831T3 (en) 1999-06-30

Family

ID=25526607

Family Applications (1)

Application Number Title Priority Date Filing Date
GR990400922T GR3029831T3 (en) 1992-11-20 1999-03-31 Use of dimethylbenzofurans and dimethylbenzopyrans as 5-ht 3? antagonists.

Country Status (31)

Country Link
US (2) US5674868A (el)
EP (1) EP0669919B1 (el)
JP (1) JP2830952B2 (el)
KR (1) KR0166661B1 (el)
AT (1) ATE176232T1 (el)
AU (1) AU680640B2 (el)
BG (1) BG62489B1 (el)
BR (1) BR9307477A (el)
CA (1) CA2149044C (el)
CZ (1) CZ287262B6 (el)
DE (1) DE69323322T2 (el)
DK (1) DK0669919T3 (el)
ES (1) ES2129615T3 (el)
FI (1) FI952458A (el)
GR (1) GR3029831T3 (el)
HU (2) HUT72740A (el)
IL (3) IL119273A0 (el)
LV (1) LV10956B (el)
MX (1) MX9307257A (el)
NO (2) NO307690B1 (el)
NZ (1) NZ257854A (el)
OA (1) OA10158A (el)
PL (1) PL176051B1 (el)
RO (1) RO115160B1 (el)
RU (1) RU2116072C1 (el)
SG (1) SG47488A1 (el)
SK (1) SK282378B6 (el)
TW (1) TW294595B (el)
UA (1) UA49792C2 (el)
WO (1) WO1994012494A1 (el)
ZA (1) ZA938676B (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374637A (en) * 1989-03-22 1994-12-20 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives
US6235745B1 (en) 1997-04-18 2001-05-22 Janssen Pharmaceutica N.V. Use of 5HT3, antagonists for promoting intestinal lavage
BR9811676A (pt) * 1997-07-11 2000-09-19 Janssen Pharmaceutica Nv (+) norcisaprida útil para distúrbios mediados por 5-ht3 e 5-ht4
US6239122B1 (en) * 2000-01-05 2001-05-29 Joy Ann Steele Method of treatment of nausea, vomiting, and other disorders using estrogens
EP1646615B1 (en) * 2003-06-06 2009-08-26 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
EA009875B1 (ru) 2003-11-20 2008-04-28 Янссен Фармацевтика Н.В. 6-алкенил и 6-фенилалкил замещенные 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза) полимеразы
BRPI0416817A (pt) 2003-11-20 2007-03-06 Janssen Pharmaceutica Nv 2-quinolinonas e 2-quinoxalinonas 7-fenilalquila substituìdas como inibidores da poli(adp-ribose)polimerase
CA2569824C (en) 2004-06-30 2013-03-19 Janssen Pharmaceutica N.V. Phthalazine derivatives as parp inhibitors
WO2006003148A1 (en) 2004-06-30 2006-01-12 Janssen Pharmaceutica N.V. Quinazolinedione derivatives as parp inhibitors
EP1771422B1 (en) 2004-06-30 2011-02-16 Janssen Pharmaceutica NV Quinazolinone derivatives as parp inhibitors
AU2008223793B2 (en) 2007-03-08 2012-08-23 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP and TANK inhibitors
PL2215075T3 (pl) 2007-10-26 2014-04-30 Janssen Pharmaceutica Nv Pochodne chinolinonu jako inhibitory PARP
EP2260026B1 (en) 2008-03-27 2011-06-22 Janssen Pharmaceutica, N.V. Quinazolinone derivatives as tubulin polymerization inhibitors
EP2271626B1 (en) 2008-03-27 2014-11-26 Janssen Pharmaceutica, N.V. Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as parp and tubulin polymerization inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1183847A (en) * 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
ZW12187A1 (en) * 1986-07-03 1989-02-01 Janssen Pharmaceutica Nv 4-(aroylamino)piperidinebutanamide derivatives
CA1317940C (en) * 1987-09-25 1993-05-18 Georges H. P. Van Daele Substituted n-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
US5374637A (en) * 1989-03-22 1994-12-20 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives
GB9005014D0 (en) * 1990-03-06 1990-05-02 Janssen Pharmaceutica Nv N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives

Also Published As

Publication number Publication date
IL119273A0 (en) 1996-12-05
RO115160B1 (ro) 1999-11-30
RU95113434A (ru) 1997-03-10
HUT72740A (en) 1996-05-28
MX9307257A (es) 1994-05-31
ATE176232T1 (de) 1999-02-15
RU2116072C1 (ru) 1998-07-27
LV10956B (en) 1996-10-20
NO995762D0 (no) 1999-11-24
BR9307477A (pt) 1999-06-29
IL119273A (en) 2000-07-16
FI952458A0 (fi) 1995-05-19
CZ125895A3 (en) 1995-10-18
LV10956A (lv) 1995-12-20
EP0669919B1 (en) 1999-01-27
DE69323322T2 (de) 1999-09-09
HU211546A9 (en) 1995-12-28
FI952458A (fi) 1995-05-19
BG99593A (en) 1995-12-29
JPH08505840A (ja) 1996-06-25
SG47488A1 (en) 1998-04-17
PL309045A1 (en) 1995-09-18
IL107654A (en) 1998-01-04
KR0166661B1 (ko) 1999-01-15
UA49792C2 (uk) 2002-10-15
NO308530B1 (no) 2000-09-25
SK67595A3 (en) 1995-11-08
NO951980L (no) 1995-05-19
SK282378B6 (sk) 2002-01-07
NO995762L (no) 1995-05-19
ZA938676B (en) 1995-05-19
CA2149044C (en) 2007-04-03
PL176051B1 (pl) 1999-03-31
IL107654A0 (en) 1994-02-27
NO951980D0 (no) 1995-05-19
ES2129615T3 (es) 1999-06-16
BG62489B1 (bg) 1999-12-30
OA10158A (en) 1996-12-18
CZ287262B6 (en) 2000-10-11
AU5465994A (en) 1994-06-22
JP2830952B2 (ja) 1998-12-02
TW294595B (el) 1997-01-01
CA2149044A1 (en) 1994-06-09
HU9501476D0 (en) 1995-07-28
WO1994012494A1 (en) 1994-06-09
DE69323322D1 (de) 1999-03-11
US5674868A (en) 1997-10-07
NO307690B1 (no) 2000-05-15
DK0669919T3 (da) 1999-09-13
US5863923A (en) 1999-01-26
EP0669919A1 (en) 1995-09-06
NZ257854A (en) 1997-04-24
AU680640B2 (en) 1997-08-07

Similar Documents

Publication Publication Date Title
GR3029831T3 (en) Use of dimethylbenzofurans and dimethylbenzopyrans as 5-ht 3? antagonists.
AU6073596A (en) Intermediates useful in the preparation of 5-HT4 receptor antagonists
GB9524157D0 (en) Therapeutic agents
SE0104332D0 (sv) Therapeutic agents
GR3034769T3 (en) Triazole antifungal agents.
GB9204365D0 (en) Indoles
DE69720715D1 (en) Hexahydro-pyrido (4,3-b)indolderivate als antipsychotische arzneimittel
TW261614B (el)
LV11545A (lv) Pozitivas inotropas un lusitropas iedarbibas pirolohinolinona atvasinajumi
LTIP1450A (en) Azaspiroalkane derivatives,processes for their preparation and pharmaceutical compositions containing them